National Pension Service Has $338.31 Million Stake in Boston Scientific Corporation $BSX

National Pension Service boosted its holdings in Boston Scientific Corporation (NYSE:BSX) by 2.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,465,206 shares of the medical equipment provider’s stock after purchasing an additional 89,273 shares during the quarter. National Pension Service owned about 0.23% of Boston Scientific worth $338,308,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Brighton Jones LLC raised its holdings in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the last quarter. Consolidated Portfolio Review Corp bought a new stake in Boston Scientific during the second quarter worth $337,000. PFG Investments LLC raised its position in Boston Scientific by 6.4% in the 2nd quarter. PFG Investments LLC now owns 8,403 shares of the medical equipment provider’s stock valued at $903,000 after buying an additional 503 shares during the last quarter. Woodward Diversified Capital LLC purchased a new stake in Boston Scientific in the 2nd quarter valued at $205,000. Finally, J. Safra Sarasin Holding AG lifted its stake in Boston Scientific by 23.2% during the 2nd quarter. J. Safra Sarasin Holding AG now owns 200,649 shares of the medical equipment provider’s stock valued at $21,552,000 after acquiring an additional 37,784 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Performance

Shares of BSX stock opened at $93.58 on Friday. Boston Scientific Corporation has a 12 month low of $85.98 and a 12 month high of $109.50. The firm’s 50 day moving average is $95.21 and its 200 day moving average is $99.52. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $138.72 billion, a P/E ratio of 50.04, a PEG ratio of 1.64 and a beta of 0.67.

Analyst Ratings Changes

Several analysts have recently commented on the stock. UBS Group reiterated a “buy” rating on shares of Boston Scientific in a report on Wednesday, December 17th. Morgan Stanley lifted their target price on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $112.00 target price on shares of Boston Scientific in a report on Friday, January 9th. Royal Bank Of Canada increased their price target on Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Finally, Needham & Company LLC reissued a “buy” rating on shares of Boston Scientific in a research report on Thursday, January 15th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $123.89.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,739,678.74. This trade represents a 21.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. This represents a 42.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 80,204 shares of company stock valued at $7,998,563 in the last quarter. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.